Johnson & Johnson has added another piece to the data behind its effort to move Tecvayli into earlier-line therapy for multiple myeloma, including the first relapse setting. In the MajesTEC-9 trial, ...
Self-hosted agents execute code with durable credentials and process untrusted input. This creates dual supply chain risk, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results